Advertisement

Topics

Acceleron begins dosing in Phase II trial of ACE-083 to treat CMT

19:00 EDT 1 Aug 2017 | Net Resources International

Acceleron Pharma has started dosing patients in a Phase II clinical trial of its therapeutic candidate ACE-083 for the treatment of Charcot-Marie-Tooth disease (CMT) patients.

Original Article: Acceleron begins dosing in Phase II trial of ACE-083 to treat CMT

NEXT ARTICLE

More From BioPortfolio on "Acceleron begins dosing in Phase II trial of ACE-083 to treat CMT"

Quick Search
Advertisement
 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...